Repare Therapeutics Valuation
| RPTX Stock | USD 1.51 0.01 0.66% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Repare Therapeutics holds a recent Real Value of $2.75 per share. The prevailing price of the company is $1.51. Our model determines the value of Repare Therapeutics from analyzing the company fundamentals such as Shares Owned By Insiders of 1.20 %, return on equity of -0.72, and Current Valuation of (58.09 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Repare Therapeutics' valuation include:
Price Book 0.5177 | Enterprise Value | Enterprise Value Ebitda 0.5798 | Price Sales 60.3598 | Enterprise Value Revenue 0.0201 |
Undervalued
Today
Please note that Repare Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Repare Therapeutics is based on 3 months time horizon. Increasing Repare Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Repare Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Repare Stock. However, Repare Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.51 | Real 2.75 | Target 6.5 | Hype 1.51 | Naive 1.57 |
The intrinsic value of Repare Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Repare Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Repare Therapeutics helps investors to forecast how Repare stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Repare Therapeutics more accurately as focusing exclusively on Repare Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Repare Therapeutics' intrinsic value based on its ongoing forecasts of Repare Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Repare Therapeutics' closest peers.
Repare Therapeutics Cash |
|
Repare Valuation Trend
Analysing the historical paterns of Repare Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Repare Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Repare Therapeutics Total Value Analysis
Repare Therapeutics is at this time anticipated to have valuation of (58.09 M) with market capitalization of 64.77 M, debt of 1.93 M, and cash on hands of 282.09 M. The negative valuation of Repare Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Repare Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(58.09 M) | 64.77 M | 1.93 M | 282.09 M |
Repare Therapeutics Investor Information
About 69.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.52. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Repare Therapeutics recorded a loss per share of 3.02. The entity had not issued any dividends in recent years. Based on the key indicators related to Repare Therapeutics' liquidity, profitability, solvency, and operating efficiency, Repare Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Repare Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Repare Therapeutics has an asset utilization ratio of 30.3 percent. This suggests that the Company is making $0.3 for each dollar of assets. An increasing asset utilization means that Repare Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Repare Therapeutics Ownership Allocation
Repare Therapeutics owns a total of 42.89 Million outstanding shares. Over half of Repare Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Repare Therapeutics Profitability Analysis
The company reported the previous year's revenue of 53.48 M. Net Loss for the year was (84.69 M) with profit before overhead, payroll, taxes, and interest of 395 K.About Repare Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Repare Therapeutics. We calculate exposure to Repare Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Repare Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 51.6 M | 54.1 M | |
| Pretax Profit Margin | (1.56) | (1.63) | |
| Operating Profit Margin | (1.75) | (1.84) | |
| Net Loss | (1.58) | (1.66) | |
| Gross Profit Margin | 0.96 | 1.01 |
Repare Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 42.4 M |
Repare Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Repare Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Repare we look at many different elements of the entity such as Repare's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Repare Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Repare Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Repare Therapeutics' worth.Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.